Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 1012345...10...Last »

Bayer, Novartis clash with UK doctors over use of cheap eye drug

Bayer is weighing legal action and Novartis has expressed concern at plans by doctors in the north of England to defy official guidance by using a cancer medicine as a cheap eye drug.

Read More »

Daiichi Sankyo’s Tumor Drug Meets Primary Endpoint in Late-Stage Study

Daiichi Sankyo announced that its Phase III ENLIVEN trial of pexidartinib met its primary endpoint.

Read More »

X-Spine Systems to Shut Down, Lays Off 54 Employees

X-Spine Systems, a division of Xtant Medical Systems, is shutting down a facility in Ohio and terminating 54 people between December and February 2018.

Read More »

Kirin Cashes Out of Amgen Drug Joint Venture for $780 Million

Amgen and Kirin Holdings decided to dissolve their joint venture, Kirin-Amgen, which will become a wholly owned subsidiary of Amgen.

Read More »

New Jersey sues OxyContin maker, links marketing to opioid crisis

New Jersey sued Purdue Pharma LP, maker of the chronic pain medication OxyContin, accusing the company of engaging in deceptive marketing practices that contributed to what it called the state’s opioid crisis.

Read More »

Voyager Sinks as Sanofi Genzyme Opts Out of Parkinson’s Gene Therapy Program

Shares of Voyager Therapeutics fell more than 12 percent in premarket trading after the company announced Sanofi Genzyme walked away from its $845 million gene therapy treatment for Parkinson’s disease.

Read More »

AstraZeneca, Incyte plan pivotal lung cancer trial

AstraZeneca stepped up its bet on immunotherapy combo treatments to fight lung cancer by signing a deal with Incyte as they will start a final-stage study in 2018.

Read More »

U.S. states allege broad generic drug price-fixing collusion

A large group of U.S. states accused key players in the generic drug industry of a broad price-fixing conspiracy, moving to widen an earlier lawsuit to add many more drugmakers and medicines in an action that sent some company shares tumbling.

Read More »

Pfizer beats Q3 2017 profit estimates

Pfizer Inc.’s third-quarter profit beat market estimates and the company raised its full-year 2017 earnings forecast.

Read More »

Merck Drops After Withdrawing European App for Wonder Drug Keytruda

Merck announced that the company pulled its application for Keytruda (pembrolizumab) in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non-small cell lung cancer from the European Medicines Agency.

Read More »

Kymera Emerges Out of Stealth Mode With $30M and a Top Team of Drug Hunters

Kymera Therapeutics launched with a $30 million Series A financing. The round was led by Atlas Venture, which co-founded, seeded and incubated the company, along with Lilly Ventures and Amgen Ventures.

Read More »

Publicis Health Integrates Publicis LifeBrands Medicus Into Saatchi & Saatchi Wellness

Publicis Health announced the integration of Publicis LifeBrands Medicus (PLBM) into Saatchi & Saatchi Wellness (SSW) to create a new Wellness Intelligence-driven agency designed to help health and wellness-oriented audiences navigate the expanding “Wellness Culture.”

Read More »

Endo’s third-quarter 2017 earnings forecast tops estimates

Endo International Plc forecast earnings for the third quarter well above analysts’ estimates amid a lawsuit filed by it against U.S. health regulators that seeks to protect the drugmaker’s blood pressure drug franchise.

Read More »

Investor group presses U.S. drug companies on opioid controls

U.S. shareholder activists are addressing a soaring death toll from opioid drug abuse, asking companies that make and distribute the painkillers to review the risks their businesses could face from their role in the sector.

Read More »

AstraZeneca licenses genetic disease drug to Mereo BioPharma

Mereo BioPharma agreed a licensing deal and acquisition option for a rare disease drug from AstraZeneca as the big drugmaker continues to divest non-core assets.

Read More »

Novartis to buy French cancer specialist AAA for $3.9 billion

Novartis agreed to buy French-based Advanced Accelerator Applications (AAA) for $3.9 billion, giving it a platform in radiopharmaceuticals and access to a new therapy for the kind of cancer that killed Steve Jobs.

Read More »

Sumitomo Dainippon, Poxel Strike Diabetes Deal

Sumitomo Dainippon Pharma Co. Ltd. and Poxel SA announced the signing of a strategic partnership for the development and commercialization of Imeglimin – an investigational therapeutic agent for type 2 diabetes – in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries. Poxel is a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders.

Read More »

Cambridge-Based Wave Life Sciences Expands Into New Facility Designed to House Up to 200 Employees

Wave Life Sciences officially opened a new state-of-the art manufacturing facility to support advancement of the company’s stereopure nucleic acid platform.

Read More »

AbbVie says Humira sales will balloon to $21 billion in 2020, shares rise

AbbVie expect its flagship drug Humira to bring $21 billion in sales by 2020, about $3 billion higher than its expectation two years ago.

Read More »

Merck profit beat clouded by NotPetya attack, shares dip

Merck & Co. reported profit ahead of Street estimates on strong sales of its cancer drug Keytruda, but total revenue fell in third-quarter 2017 from disruptions due to the NotPetya cyber attack and loss of market share for many of the company’s older drugs.

Read More »

Page 1 of 1012345...10...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom